{"id":754140,"date":"2023-05-03T07:17:54","date_gmt":"2023-05-03T11:17:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-first-quarter-2023-financial-results-and-highlights-recent-corporate-developments\/"},"modified":"2023-05-03T07:17:54","modified_gmt":"2023-05-03T11:17:54","slug":"eyepoint-pharmaceuticals-reports-first-quarter-2023-financial-results-and-highlights-recent-corporate-developments","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-first-quarter-2023-financial-results-and-highlights-recent-corporate-developments\/","title":{"rendered":"EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments"},"content":{"rendered":"
\n

\n \u2013 Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration (AMD); topline data anticipated in 4Q 2023<\/em>
\n \n <\/p>\n

\n \u2013 Enrollment ahead of schedule in the Phase 2 PAVIA clinical trial evaluating EYP-1901 in non-proliferative diabetic retinopathy (NPDR); trial size reduced based on robust body of clinical evidence and proof-of-concept for vorolanib and EYP-1901<\/em>\n <\/p>\n

\n \u2013 YUTIQ net product revenue increased 60% to $7.4 million compared with $4.6 million in 1Q 2022 <\/em>\n <\/p>\n

\n \u2013 Management to host a conference call and webcast today at\u00a08:30 a.m. ET <\/em>\n <\/p>\n

WATERTOWN, Mass., May 03, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the first quarter ended\u00a0March 31, 2023\u00a0and highlighted recent corporate developments.<\/p>\n

\u201cIn the first quarter, we continued to successfully execute on our key objectives across all areas of the business. Most importantly, we announced the completion of enrollment in our Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet AMD. We were particularly pleased by the high level of physician and patient interest, which resulted in the oversubscription of the trial to 160 patients compared to the original target of 144 patients. We look forward to announcing topline data from the DAVIO 2 trial in the fourth quarter of this year,\u201d said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. \u201cCombined with the Phase 1 DAVIO results, the Phase 2 DAVIO 2 data read-out will represent the most robust dataset among tyrosine kinase inhibitors in development for wet AMD. In addition, the body of evidence for EYP-1901 and vorolanib from both the clinical and non-clinical data to-date, combined with the drug\u2019s proven anti-VEGF pharmacological mechanism across VEGF-mediated retinal diseases, support a strong proof-of-concept for EYP-1901 in NPDR. Accordingly, we have modified the trial size to enroll a minimum of 60 patients for the Phase 2 PAVIA clinical trial evaluating EYP-1901 in NPDR, which allows for enrollment completion ahead of schedule in the second quarter of this year, an accelerated path to Phase 2 data in the first half of 2024 and, subsequently, an earlier initiation timeline for the Phase 3 clinical trials. We look forward to providing additional clinical updates in the quarters to come.\u201d<\/p>\n

Ms. Lurker continued, \u201cOnce again, our commercial team delivered a strong quarter with $7.4 million in YUTIQ net product revenue, a 60% increase over the first quarter of 2022. We remain very pleased with the performance of YUTIQ and the terrific results our commercial team are producing.\u201d<\/p>\n

\n R&D Highlights and Updates<\/strong>\n <\/p>\n